London, UK; 21 October 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the successful closing of the European Mutual Recognition Procedure (MRP) in France for Sativex® oromucosal spray in the treatment of spasticity due to Multiple Sclerosis (MS) and a resulting recommendation for approval by the French authorities.
Medical Cannabis News & Information
Washington, DC: The US Food and Drug Administration has approved two clinical trials to assess the efficacy of cannabidiol (CBD), a nonpsychoactive plant cannabinoid, in the treatment of intractable pediatric epilepsy. The two approved trials will take place at New York Medical School and at the University of California at San Francisco, according to an online report in the journal O'Shaughnessy's. The cannabidiol formulations in the trials will be provided by British biotechnology firm GW Pharmaceuticals, which produces organic cannabinoid extract medicines, including Sativex.
New research has shown that the non-hallucinogenic components of cannabis could act as effective anti-cancer agents.
The anti-cancer properties of tetrahydrocannabinol (THC), the primary hallucinogenic component of cannabis, has been recognised for many years, but research into similar cannabis-derived compounds, known as cannabinoids, has been limited.
The study was carried out by a team at St George’s, University of London. It has been published in the journal Anticancer Research.
According to a study published earlier this year by the National Institute of Health, activation of the body’s cannabinoid receptors – something which cannabis does naturally – can protect against sepsis, a serious inflammatory illness which is due to a severe reaction to bacteria or germs, which often proves fatal.
During the study, which used mice subjects, researchers found that activation of the cannabinoid receptor 2 (CB2R) can “significantly extend the survival rate and decrease serum proinflammatory cytokines” in those with sepsis.
A National Institute of Health study published earlier this year found that cannabis may treat celiac disease by activating the body’s natural cannabinoid receptors. Celiac disease is an autoimmune disorder of the small intestine which some people are genetically predisposed to.
The study, which was conducted by researchers at the Department of Biomedical Sciences at the University of Teramo in Italy, aimed to “investigate the expression of CBR [cannabinoid receptors] at transcriptional and translational levels in the duodenal mucosa of untreated celiac patients, celiac patients on a gluten-free diet for at least 12 months and control subjects. Also biopsies from treated celiac patients cultured ex vivo with peptic-tryptic digest of gliadin were investigated.”